SOURCE: Inotek Pharmaceuticals

Inotek Pharmaceuticals

April 27, 2010 09:04 ET

Inotek Pharmaceuticals to Present New Preclinical Data on Novel Mechanism of Action for Lead Glaucoma Candidate INO-8875

Data to Be Presented in Poster Presentations at ARVO 2010 Annual Meeting

LEXINGTON, MA--(Marketwire - April 27, 2010) -  Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, announced that the Company will present results from preclinical studies demonstrating the mechanism of action for the Company's lead glaucoma candidate, INO-8875. INO-8875 has successfully completed a single-dose Phase 1/2 trial in glaucoma and is expected to enter Phase 2 trials with an eye-drop formulation in mid-2010. The data will be presented in poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Ft. Lauderdale, FL, being held from May 2-6, 2010.

The poster presentations are as follows:

Sunday, May 2, 2010: 2:45 p.m. - 4:30 p.m.
  "Ocular Pharmacokinetics and Tissue Distribution of INO-8875, an Adenosine A1 Agonist, in Preclinical Species by Quantitative Whole Body Autoradiography (QWBA) and Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)" (Poster #A349)
Tuesday, May 4, 2010: 1:45 p.m. - 3:30 p.m.
  "INO-8875, an Adenosine A1 Agonist, Lowers Intraocular Pressure Through the Conventional Outflow Pathway" (Poster #D780)

About Inotek
Inotek is a leader in the development of innovative drug candidates that address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate INO-8875 is a potential first-in-class eye-drop treatment for glaucoma that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single doses applied to the eye in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in retinal diseases, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit

Contact Information

  • Company Information:
    Adam L. Muzikant, Ph.D.
    Senior Director, Business Development
    Inotek Pharmaceuticals
    (781) 676-2100

    Media Relations:
    Sarah Cavanaugh
    MacDougall Biomedical Communications
    Email Contact
    (781) 235-3060